PHMMF (Pharma Mar) Debt-to-Asset : 0.15 (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Pharma Mar Debt-to-Asset?

Pharma Mar's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $10.3 Mil. Pharma Mar's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $43.2 Mil. Pharma Mar's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $366.1 Mil. Pharma Mar's debt to asset for the quarter that ended in Dec. 2024 was 0.15.

Pharma Mar Debt-to-Asset Historical Data

The historical data trend for Pharma Mar's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar Debt-to-Asset Chart

Pharma Mar Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.17

0.13

0.11

0.13

0.15

Pharma Mar Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.13	0.12	0.12	0.12	0.15

Competitive Comparison of Pharma Mar's Debt-to-Asset

For the Biotechnology subindustry, Pharma Mar's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharma Mar's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Debt-to-Asset falls into.

Save Embed

Pharma Mar Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Pharma Mar's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(10.311	+	43.171)	/	366.119
	=	0.15

Pharma Mar's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(10.311	+	43.171)	/	366.119
	=	0.15

Pharma Mar (OTCPK:PHMMF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Pharma Mar Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Pharma Mar's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharma Mar Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (OTCPK:PHMMF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

PHMe:UK 0RC6:UK PHM:Spain PMRA:Germany PHM:Austria

Address

Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770

Website

http://www.pharmamar.com

Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.